ライフサイエンスコーパス: cytoreduction

1 gnificantly sensitized cells for RAP-induced cytoreduction.

2 = 117; appendiceal cancer, n = 57) underwent cytoreduction.

3 ogression as well as survival after surgical cytoreduction.

4 fit in PFS or OS after optimal or suboptimal cytoreduction.

5 ative therapeutic options other than primary cytoreduction.

6 a reported to have undergone optimal primary cytoreduction.

7 patients reported to have undergone optimal cytoreduction.

8 ery are commonly required to achieve optimal cytoreduction.

9 f 75%, and an accuracy of 77% for suboptimal cytoreduction.

10 selected patients may benefit from secondary cytoreduction.

11 id versus did not undergo interval secondary cytoreduction.

12 They have used different regimens for cytoreduction.

13 dual tumor cells after chemotherapy-mediated cytoreduction.

14 ne therapy for ovarian cancer after surgical cytoreduction.

15 The rate of optimal cytoreduction ( 1 cm residual disease) was 78%.

16 Radiation-induced cytoreduction/ablation followed by donor hematopoietic c

17 studies demonstrate for the first time that cytoreduction/ablation with ALS combined with sirolimus

18 Optimal cytoreduction achieves the best outcomes.

19 val cytoreduction are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to

20 Despite an aggressive approach of surgical cytoreduction and adjuvant combination chemotherapy, ova

21 o more effective than rapamycin in achieving cytoreduction and apoptosis in MM cells.

22 d to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and re

23 vely active AKT were remarkably sensitive to cytoreduction and G(1) arrest induced by CCI-779 with ID

24 s of PSM on the basis of rates of incomplete cytoreduction and G3-5 morbidity (NCI-CTCAE v3).

25 nd 149 th case, respectively, for incomplete cytoreduction and G3-5 morbidity.

26 ative allogeneic HCT (auto/alloHCT) provides cytoreduction and graft-versus-myeloma effects.

27 Thirteen patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3

28 ere examined in patients undergoing surgical cytoreduction and intraperitoneal chemotherapy for epith

29 h epithelial appendiceal neoplasm undergoing cytoreduction and intraperitoneal chemotherapy treatment

30 h epithelial appendiceal neoplasm undergoing cytoreduction and intraperitoneal chemotherapy.

31 positive correlation between percent maximal cytoreduction and log median survival time, and this cor

32 DA-EPOCH-F/R safely provides tumor cytoreduction and lymphocyte depletion, thereby offering

33 minimize nephrotoxicity, is a very effective cytoreduction and mobilization regimen in patients with

34 with caution when deciding between surgical cytoreduction and neoadjuvant chemotherapy.

35 ects were treated without pretransplantation cytoreduction and remained on ADA enzyme-replacement the

36 e drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and hist

37 ancer, neoadjuvant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction a

38 ing may counteract the beneficial effects of cytoreduction at higher doses of HU and represents an ad

39 In addition to providing cytoreduction at myeloablative dose intensity, condition

40 s did not (54.0%) undergo interval secondary cytoreduction at the third assessment (P = .005), and ol

41 Patients who received complete cytoreduction benefited most, with median survival varyi

42 latelet count, age, JAK-2 V617F mutation, or cytoreduction (beta = 3.53, P = .001).

43 tly, the combination of antibody CD19-DE and cytoreduction by chemotherapy (dexamethasone, vincristin

44 Current treatment options for MPNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ru

45 Tumor cytoreduction by preoperative chemoradiation can increas

46 = .013), debulking surgery (completeness of cytoreduction [CCR], 2 or 3; P < .001), and not using HI

47 mucinous neoplasm is minimally invasive and cytoreduction complete, these treatments result in a 20-

48 Patients received myeloablative cytoreduction consisting of hyperfractionated total body

49 proportion of each cohort undergoing maximal cytoreduction, dose-intensity of the platinum compound a

50 ation with double AT markedly augments tumor cytoreduction, effecting not only higher CR rates but al

51 domly assigned to receive secondary surgical cytoreduction followed by chemotherapy and 208 to receiv

52 (75 mg/m2) was administered for bone marrow cytoreduction, followed by infusion of autologous, gene-

53 exchange should be promptly initiated before cytoreduction for hyperviscosity-related symptoms.

54 Rates of incomplete cytoreduction, G3-5 morbidity, and postoperative mortali

55 s estimated, cohorts with < or = 25% maximal cytoreduction had a mean weighted median survival time o

56 , whereas cohorts with more than 75% maximal cytoreduction had a mean weighted median survival time o

57 minimally decreased at the first and second cytoreductions had a significantly inferior 5-year survi

58 al advantage associated with optimal primary cytoreduction has been consistent and reproducible.

59 vanced ovarian cancer after primary surgical cytoreduction have reported a survival advantage with re

60 re associated with higher odds of incomplete cytoreduction in BRCA wild-type HGSOC (multiple regressi

61 These data imply that the aim of cytoreduction in essential thrombocythemia should be to

62 thelial ovarian cancer who underwent primary cytoreduction in institution A between 1999 and 2005 wer

63 phy (CT) scans to predict suboptimal primary cytoreduction in patients treated for advanced ovarian c

64 b tiuxetan-based NMAT would facilitate early cytoreduction in such patients promoting improved long-t

65 ccuracy rates of CT predictors of suboptimal cytoreduction in the original cohorts could not be confi

66 The rate of cytoreduction is a powerful, independent prognostic fact

67 riate surgical selection criteria, secondary cytoreduction is associated with a significant prolongat

68 and the recognition that aggressive surgical cytoreduction is beneficial, the majority of patients di

69 In conclusion, cytoreduction is important for the engraftment of gene-t

70 ydroxyurea is still the "gold standard" when cytoreduction is needed, even though pegylated IFN-alfa-

71 anaged by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control i

72 At day 0, the degree of cytoreduction (lymphopenia, neuthropenia, and thrombocyt

73 and/or comorbidities precluding microscopic cytoreduction may be considered for alternative therapeu

74 ic chemotherapy treatments before definitive cytoreduction may facilitate the feasibility and improve

75 logically proven advanced HGSC after primary cytoreduction (mean age +/- standard deviation, 60 years

76 101 patients evaluable for peripheral blast cytoreduction, MTXPG concentrations were higher in patie

77 y benefit from effective yet minimally toxic cytoreduction of endogenous hematopoietic stem cells (HS

78 Rapid cytoreduction of leukemia occurred in the blood, with th

79 her metastatic solid tumors is that surgical cytoreduction of tumor volume is highly correlated with

80 ts were the only CT predictors of suboptimal cytoreduction on univariate (P < .02) and multivariate a

81 e allogeneic bone marrow engraftment without cytoreduction or T-cell depletion of the host, and elimi

82 < 0.001) and the ability to achieve complete cytoreduction (P < 0.001).

83 e interval [CI]: 1.009, 1.07) and suboptimal cytoreduction (P = .03; HR, 2.13; 95% CI: 1.12, 4.07) we

84 w Drosha expression with suboptimal surgical cytoreduction (P=0.02).

85 activity of HDCTX (10% with > or = 50% tumor cytoreduction), PBSC mobilization with HDCTX should be l

86 Hepatic metastases may be amenable to cytoreduction, radiofrequency ablation, embolization alo

87 y for cure (which is achieved rarely) or for cytoreduction, radiological intervention (by chemoemboli

88 his inferior response resulted from impaired cytoreduction rather than delayed hemopoietic recovery.

89 de pathology and tumors amenable to complete cytoreduction, recurrence of PMP is common.

90 Accurate staging and maximum cytoreduction remain essential goals in primary surgery

91 Although interval secondary cytoreduction resulted in no notable long-term differenc

92 cal sibling donors but no pretransplantation cytoreduction results in T-lymphocyte engraftment and co

93 g second-look surgery, secondary or interval cytoreduction, second-line chemotherapy, hormonal therap

94 d if there is a high likelihood of achieving cytoreduction to < 1 cm (ideally to no visible disease)

95 isk profile or a low likelihood of achieving cytoreduction to < 1 cm of residual disease (ideally to

96 laparoscopy first is reasonable and that if cytoreduction to < 1 cm of residual disease seems feasib

97 ked to consent to a postoperative CT scan if cytoreduction to < or = 1 cm RD was reported.

98 nt at baseline achieved adequate bone marrow cytoreduction to receive standard-dose iodine I 131 tosi

99 has shifted the paradigm from pre-transplant cytoreduction to tumor control via donor lymphocytes.

100 median disease-free interval after complete cytoreduction was 24 months.

101 Although complete cytoreduction was achieved in 55% (53/97), disease recur

102 Each 10% increase in maximal cytoreduction was associated with a 5.5% increase in med

103 A complete second cytoreduction was associated with an improved 5-year sur

104 During the platinum era, maximal cytoreduction was one of the most powerful determinants

105 The rate of cytoreduction was related to event-free survival (EFS) a

106 All patients were engrafted after cytoreduction with busulfan, cyclophosphamide, and etopo

107 Both regimens comprised preconditioning cytoreduction with hydroxyurea and azathioprine starting

108 tic complications demonstrated that platelet cytoreduction with hydroxyurea is effective in reducing

109 as a reasonable choice for women who require cytoreduction with manageable toxicities and validate on

110 In 110 patients, cytoreduction with one or two courses of vinblastine plu

111 Cytoreduction with stereotactic body radiation therapy (